Boots UK has expanded its peptide-focused skincare section by 40% across 600 stores, adding 12 new brands and 45 SKUs. The move signals that peptides have crossed the chasm from specialty ingredient to mass-market staple.
What Boots Is Doing
The expanded section, branded Peptide+, features dedicated shelf space organized by peptide type — signal peptides (Matrixyl, KTTKS), carrier peptides (GHK-Cu), neurotransmitter-inhibiting peptides (Argireline, Syn-Ake), and enzyme-inhibitor peptides. Shelf labels include QR codes linking to ingredient explainers. Boots has trained 2,000 beauty advisors on peptide science basics.
The UK retailer’s move follows a 67% year-over-year increase in peptide-related search queries on boots.com. The highest-growth search terms were peptide serum for sensitive skin (+124%), copper peptide moisturiser (+89%), and Argireline eye cream (+73%).
Mass-Market vs Premium: The Two-Track Strategy
Boots Peptide+ section is split into two tiers: Peptide Essential (brands like No7, Garnier, L’Oreal Paris, priced 12-35 GBP) and Peptide Science (brands like Medik8, Drunk Elephant, priced 35-85 GBP). This dual-track approach mirrors what we saw with vitamin C and retinol.
What is different about peptides is the speed. Vitamin C took roughly 8 years to go from premium-only to mass-market ubiquity. Retinol took about 7 years. Peptides are tracking closer to 4-5 years, accelerated by TikTok and Reddit skincare communities.
Broader Context
In the US, Ulta Beauty added 30 peptide-focused SKUs in Q1 2026. In China, Tmall peptide skincare category grew 92% year-over-year in H1 2026. The global peptide skincare market is projected to reach .2 billion by 2028, growing at 11.3% CAGR.
The most interesting signal is the rise of peptide + sensitive skin queries. Consumers are increasingly choosing peptides as an alternative to retinol for anti-aging when they cannot tolerate retinoids.
Source: Boots UK press release, July 2026; Cosmoprof Bologna 2026 retail trend report; Mintel Beauty & Personal Care Global Market Report 2026
